Four-year data from ILLUMENATE Pivotal trial reaffirms safety profile of Philips Stellarex low-dose Drug-Coated Balloon


You May Also Like

MacroGenics Provides Update on Corporate Progress and Second Quarter 2017 Financial Results

ROCKVILLE, Md., Aug. 02, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical ...

TESARO Announces Participation at Two Investor Conferences

WALTHAM, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...